PT-141 (Vyleesi) is FDA approved — quick facts

Quick reference since this one also surprises people: PT-141 (bremelanotide) is FDA approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, with phase 3 RCT support from the RECONNECT program.

It is a melanocortin receptor agonist given by subcutaneous injection. The approved effect size is modest but real, which is a more honest framing than the marketing usually gives it.